Renal Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
01/23/2010

Renal Cancer Market is Forecast to Show High Growth to 2016

Online PR News – 23-January-2010 – – GlobalData estimates that the global renal cancer was valued at $857m in 2009 and is forecast to grow at a compound annual growth rate (CAGR) of 9.5% for the next seven years to reach $1.7 billion by 2016. This high growth forecast is primarily attributed to population growth and high diagnosis and treatment seeking rates. In addition, the renal cancer market growth will continue to be driven by the strong pipeline landscape with new combination and first-in-class drugs with better survival rates and safety and efficacy profiles.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Renal-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData’s research indicates that the prevailing pipeline landscape is weak with few players and none of their products seem to be satisfying the unmet needs of the renal cancer market. The current market provides large scope for pipeline drugs that are strong in terms of overall survival rates, efficacy and safety. As patients become more aware of the latest technological developments, increased efficacy, tolerability and safety profiles will be the key factors that drive the acceptance and market penetration of pipeline products. As the marketed products do not serve the unmet needs in the market, there will continue to be opportunities for stronger pipeline candidates. However, since a majority of the pipeline products are combination and first-in-class drugs with proven superiority in terms of therapeutic performance, the existing market leaders will face significant challenges to their market shares.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Renal-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData expects that F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Amgen Inc., and WILEX AG. will become the leading competitors in the global renal cancer market. These companies, with some of the most technologically advanced products in their pipeline portfolios, are expected to attract the largest share of investor attention in the coming years.
The existing market landscape remains moderately competitive with only six key products approved. This scenario could change in the near future following multiple product launches by the leading and emerging manufacturers who are concentrating on novel therapies such as targeted therapies, EGFR, RAF inhibitors and LAK and NK cells enhancers.

GlobalData, the industry analysis specialist, has released its new report, “Renal Cancer – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global renal cancer market. The report identifies the key trends shaping and driving the dynamism in the global renal cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global renal cancer market.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Renal-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportsotre